within Pharmacolibrary.Drugs.ATC.A;

model A04AA02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 6.166666666666666e-06,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00282,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0024300000000000003,
    k12             = 0.75,
    k21             = 0.75
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A04AA02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Granisetron is a selective 5-HT3 receptor antagonist used primarily as an antiemetic to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and, to a lesser extent, postoperatively. It is an FDA-approved drug and is used clinically worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are for healthy adult volunteers after intravenous administration. Typical dose is a single intravenous bolus injection.</p><h4>References</h4><ol><li><p>Mason, JW, et al., &amp; Howell, J (2012). Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 18(10) 2913–2921. DOI:<a href=&quot;https://doi.org/10.1158/1078-0432.CCR-11-2785&quot;>10.1158/1078-0432.CCR-11-2785</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22452942/&quot;>https://pubmed.ncbi.nlm.nih.gov/22452942</a></p></li><li><p>Spartinou, A, et al., &amp; Papaioannou, A (2017). Granisetron: a review of pharmacokinetics and clinical experience in chemotherapy induced - nausea and vomiting. <i>Expert opinion on drug metabolism &amp; toxicology</i> 13(12) 1289–1297. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2017.1396317&quot;>10.1080/17425255.2017.1396317</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29057666/&quot;>https://pubmed.ncbi.nlm.nih.gov/29057666</a></p></li><li><p>Doggrell, SA (2017). Granisetron in the treatment of chemotherapy-induced nausea and vomiting (CINV) - is there still a role after comparison with palonosetron?. <i>Expert opinion on pharmacotherapy</i> 18(10) 1019–1026. DOI:<a href=&quot;https://doi.org/10.1080/14656566.2017.1342809&quot;>10.1080/14656566.2017.1342809</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28612633/&quot;>https://pubmed.ncbi.nlm.nih.gov/28612633</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A04AA02;
